📰 ReutersReutersCodex · 实盘不做把握 8/10
北京时间·🕒 发布 19:15:15时区推断·⟳ 抓取 19:15:32·⚡ 决策 08-04 19:34:45 +19m13s·83.9 天前
沃特世二季度业绩小幅超预期并上调全年收入和EPS指引
本条是沃特世同一二季度财报和全年指引上修的路透后到转述，系统已在2026-08-04 10:03 UTC起多次处理。
📄 原文Reuters↗ 原文
Waters (WAT.N) raised its annual profit and revenue forecasts on Tuesday after beating second-quarter Wall Street esti…
不做 沃特世（WAT.US）
同一二季度财报和全年指引上修催化已在2026-08-04 10:03 UTC起由wire/IR信号处理，本条Reuters为后到转述且未新增超预期事实，不重复交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 medium · price-in 风险 high ↗
关键理由
- 本条是沃特世同一二季度财报和全年指引上修的路透后到转述，系统已在2026-08-04 10:03 UTC起多次处理。
- 业绩和指引上修幅度很小：Q2 EPS 3.05美元仅略高于3.01美元预期，全年EPS区间14.45-14.65美元基本围绕14.51美元一致预期。
- 收入指引6.42亿-6.48亿美元相对此前6.41亿-6.46亿美元仅小幅上调，对约368亿美元市值的短线重定价弹性不足。
主要风险
- 重复转述不应再次推卡或延长同一催化窗口。
- 盘前未见足够大的超预期增量，若开盘追涨容易变成财报见光死。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-08-04 · 影响 none
内部库未命中比本条更强的沃特世业绩解读或上修幅度证据，无法把小幅超预期升级为可交易利好。
检索:Waters WAT Q2 2026 guidance forecast revenue EPS LSEG consensus
工具调用 · 历史记录,结果未知(3 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,584 字
Waters (WAT.N) raised its annual profit and revenue forecasts on Tuesday after beating second-quarter Wall Street estimates, helped by higher demand for its laboratory equipment and better-than-expected growth at its recently acquired businesses.
The lab equipment maker now expects 2026 adjusted profit of $14.45 to $14.65 per share, compared with its previous forecast of $14.40 to $14.60.
It sees revenue of $6.42 billion to $6.48 billion, up from $6.41 billion to $6.46 billion previously.
Analysts on average expect 2026 adjusted profit of $14.51 per share and revenue of $6.44 billion, according to data compiled by LSEG.
The company posted second-quarter adjusted profit of $3.05 per share, above analysts' average estimate of $3.01. Its quarterly revenue totaled $1.65 billion, above the market estimate of $1.62 billion.
Sales of laboratory instruments rose 5% to $240 million, while chemicals and other routinely used testing supplies recorded double-digit growth.
The biosciences and diagnostics businesses, which Waters acquired from Becton Dickinson (BDX.N), generated $817 million in their first full quarter under Waters' ownership, up 4% from their comparable year-earlier performance.
The acquired businesses make products used in biological research and clinical testing, including tools that help detect cancer and infectious diseases.
Waters expects third-quarter adjusted profit of $3.95 to $4.05 per share and revenue of $1.75 billion to $1.76 billion. Analysts expect adjusted profit of $3.99 per share and revenue of $1.75 billion.
The lab equipment maker now expects 2026 adjusted profit of $14.45 to $14.65 per share, compared with its previous forecast of $14.40 to $14.60.
It sees revenue of $6.42 billion to $6.48 billion, up from $6.41 billion to $6.46 billion previously.
Analysts on average expect 2026 adjusted profit of $14.51 per share and revenue of $6.44 billion, according to data compiled by LSEG.
The company posted second-quarter adjusted profit of $3.05 per share, above analysts' average estimate of $3.01. Its quarterly revenue totaled $1.65 billion, above the market estimate of $1.62 billion.
Sales of laboratory instruments rose 5% to $240 million, while chemicals and other routinely used testing supplies recorded double-digit growth.
The biosciences and diagnostics businesses, which Waters acquired from Becton Dickinson (BDX.N), generated $817 million in their first full quarter under Waters' ownership, up 4% from their comparable year-earlier performance.
The acquired businesses make products used in biological research and clinical testing, including tools that help detect cancer and infectious diseases.
Waters expects third-quarter adjusted profit of $3.95 to $4.05 per share and revenue of $1.75 billion to $1.76 billion. Analysts expect adjusted profit of $3.99 per share and revenue of $1.75 billion.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。